A preliminary assessment of the acute and subchronic toxicity profile of Phase2: An α-amylase inhibitor

Kuzhuvelil B. Harikumar, Aranjany M. Jesil, Mandumpal C. Sabu, Ramadasan Kuttan

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Phase2®, which has been reported to reduce body weight by its inhibition of α-amylase, was evaluated for toxicity in young adult male and female Wistar rats (10 animals/dose group). Evaluations included mortality, change in body weight, food consumption pattern, organ weight, and other adverse side reactions as well as hematological, biochemical, and histopathological analyses. Acute toxicity was determined after a single dose of Phase2 by oral gavage at doses of 5.0, 1.0, and 0.5 g/kg body weight. Animals were sacrificed on fourteen days after Phase2 administration. Subchronic toxicity was determined by administering Phase2 daily for 90 days to rats, at doses of 1.0, 0.5, and 0.2 g/kg body weight. These animals were sacrificed on day 90. Acute and subchronic administration of Phase2 did not produce any adverse reactions or any significant change in the loss of body weight as compared to untreated controls, organ weight, and mortality. Administration of Phase2 did not alter the hepatic and renal function, and did not produce any change in the hematological parameters and in lipid profile. Subchronic administration produced a reduction in the food consumption after 77 days (1.0 g/kg body weight). These data indicate that acute and subchronic administration of Phase2 did not produce any toxicity to rats as evident from weight change, mortality, and limited biochemical and histopathological analyses.

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalInternational Journal of Toxicology
Volume24
Issue number2
DOIs
Publication statusPublished - 01-03-2005

All Science Journal Classification (ASJC) codes

  • Toxicology

Fingerprint Dive into the research topics of 'A preliminary assessment of the acute and subchronic toxicity profile of Phase2: An α-amylase inhibitor'. Together they form a unique fingerprint.

  • Cite this